Amyloid PET predicts atrophy in non-demented individuals: Results from the AMYPAD-PNHS

Leonard Pieperhoff[1,2,†], Luigi Lorenzini[1,2,†], Sophie Mastenbroek[1,2,3], Mario Tranfa[1,2,4], Mahnaz Shekari[5,6], Alle Meije Wink[1,2], Robin Wolz[7], Sylke Grootoonk[7], Craig Ritchie[8], Mercè Boada[9,10], Marta Marquié[9,10], Wiesje van der Flier[2,11,12], Rik Vandenberghe[13], Bernard J Hanseeuw[14,15], Pablo Martínez-Lage[16], Pierre Payoux[17], Pieter Jelle Visser[2,11], Michael Schöll[18,19,20], Giovanni Frisoni[21], Andrew Stephens[22], Christopher Buckley[23], Gill Farrar[23], Frank Jessen[24], Oriol Grau-Rivera[5], Juan Domingo Gispert[5], David Vállez García[1,2,5], Henk Mutsaerts[1,2], Frederik Barkhof[1,2] and Lyduine E. Collij[1,2,3] *on behalf of the AMYPAD consortium*

[†]**These authors contributed equally to this work.**

Abstract

The effect of β-amyloid (Aβ) accumulation on regional structural brain changes in the preclinical stages of Alzheimer's disease (AD) is not well understood. Consequently, it is not clear whether brain volume could be used as a secondary outcome in prevention trials. We aimed to determine the effect of cortical Aβ pathology on regional brain atrophy in a non-demented population and assess the interaction effect of sex and *APOE*-ε4 carriership.

We included 1329 participants from the prospective multi-center AMYPAD Prognostic and Natural History Study who underwent [^{18}F]Flutemetamol or [^{18}F]Florbetaben amyloid-PET and T1-weighted MRI, with longitudinal data for 684 participants (median follow-up=3.4 years). Linear mixed models assessed the effect of baseline Aβ burden through the Centiloid approach on longitudinal changes in regional gray matter volume and thickness. A second model investigated the effects of sex or *APOE*-ε4 carriership. We performed power analyses to estimate the number of required subjects in an early 48-month randomized-controlled secondary prevention trial to detect 20% to 30% efficacy of anti-Aβ interventions on regional atrophy measures.

A total of 1329 subjects (56% female) with an age of 68.2 (±8.78 years) were included, 117 (8.8%) and 260 (19.6%) of whom were considered to have intermediate and elevated Aβ respectively. Baseline global Aβ was predictive of widespread atrophy in several brain regions, most strongly in the medial-temporal lobe, cingulate cortex, and precuneus. These associations were largely independent of sex and *APOE*-ε4 genotype. Aβ burden had a larger

impact on changes in thickness than volume. Using hippocampal or lateral ventricular volume as an outcome measure resulted in the smallest sample size to detect Aβ-related treatment effects.

In a non-demented population, baseline amyloid is predictive of atrophy in several brain regions. Regionalized measures of cortical thickness, in addition to hippocampal volume, showed to be more sensitive to early Aβ deposition and could be candidate biomarkers in early primary or secondary AD prevention trials.

Author affiliations:

1 Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, 1081HV, the Netherlands.

2 Amsterdam Neuroscience, Brain imaging, Amsterdam, 1081HV, the Netherlands.

3 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, 211 46, Sweden.

4 Department of Advanced Biomedical Sciences, University "Federico II", Naples, 80131, Italy.

5 Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, 08005, Spain.

6 Hospital del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain

7 IXICO, London, EC1A 9PN, United Kingdom

8 Scottish Brain Sciences, Edinburgh, EH12 9DQ, Scotland

9 Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona, 08014, Spain

10 Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, 28031, Spain

11 Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, 1081HV, The Netherlands

12 Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, 1081HV, The Netherlands

13 Katholieke Universiteit Leuven, Leuven, 3000, Belgium

14 Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium

15 Institute of Neuroscience, Université catholique de Louvain, Brussels, 1200, Belgium

16 Center for Research and Advanced Therapies. CITA Alzheimer Foundation, Donostia-San Sebastián, 20009, SPAIN

17 Université Toulouse 3 , Inserm, ToNIC Toulouse NeuroImaging Center, Toulouse, 31024, France

18 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, 413 45, Sweden

19 Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, 411 26, Sweden

20 Dementia Research Centre, Institute of Neurology, University College London, London, WC1N 3AR, United Kingdom

21 Hôpitaux Universitaires de Genève, Geneva, 1205, Switzerland

22 Life Molecular Imaging, Berlin, 13353, Germany

23 GE HealthCare, Buckinghamshire, HP8 4SP, United Kingdom

24 Department of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, 50937, Germany

Correspondence to: Leonard Pieperhoff

l.pieperhoff@amsterdamumc.nl

+31 615231729

de Boelelaan 1117, PK-1X014, Amsterdam Universitair Medische Centra

Amsterdam, 1081HV, the Netherlands

Running title: Amyloid PET predicts atrophy

Keywords: Centiloid; MRI; Gray Matter Thickness; Gray Matter Volume; Preclinical Alzheimer's Disease; Cognitively Unimpaired

Introduction

Brain atrophy is a key feature of neurodegenerative diseases and a common surrogate endpoint in Alzheimer's disease (AD) clinical trials.[1] In its clinical stage, AD-associated atrophy and cognitive decline are closely linked to tau deposition.[2] However, as the field of anti-amyloid therapy is shifting towards early intervention, there is a need to understand the effect of early amyloid-beta (Aβ) accumulation on atrophy in preclinical stages of the disease. Large longitudinal studies are required to provide a robust and sensitive brain atrophy outcome measure for early secondary or primary prevention trials.

AD-associated atrophy has commonly been described first in medial-temporal areas, followed by more widespread involvement of the neocortex.[3–5] Accordingly, hippocampal volume has been implemented as an outcome measure in AD clinical trials.[6] Nonetheless, the effects of anti-amyloid disease modifying therapies on atrophy are unclear, with both insignificant effects and volumetric reductions being observed in trials focusing on clinical populations.[6] Loss of hippocampal volume has also been described in the preclinical stages of AD,[7,8] though several longitudinal studies have highlighted frontoparietal rather than medial-temporal atrophy patterns in relation to emerging amyloid pathology.[9,10] Also, previous work has suggested that cortical thickness has larger diagnostic separability than volume.[11] Most studies to date, however, have been limited in sample size, follow-up time, or by using binary pathological groups rather than a quantified measure of Aβ burden.[3–5,7,10,12] These observations raise the question whether hippocampal volume is the optimal regional phenotype to investigate in the context of secondary prevention anti-amyloid clinical trials.

In addition, the effects of demographic and genetic risk factors on the efficacy of anti-amyloid disease modifying therapies must be taken into account,[13] as previous studies reported that women tend to benefit less, whilst apolipoprotein E (*APOE*) ε4 carriers have

higher risk of side-effects.[14] Hence, understanding the moderating effects of demographic and genetic risk factors on the association between Aβ burden and subsequent atrophy is crucial for trial design. Previous findings regarding the effect of *APOE*-ε4 carriership have reported either increased volume loss in lateral-temporal and superior-frontal regions in a cohort of amyloid-positive subjects with mild cognitive impairment (MCI)[15] or widespread cortical thinning in prodromal AD *APOE*-ε4 non-carriers compared to carriers.[16] These discrepancies may have arisen from the isolated examination of gray matter volume and thickness, highlighting the necessity for concurrent analyses of these image-derived phenotypes (IDPs). Regarding sex differences, women show higher AD prevalence,[17] faster accumulation of cortical tau as measured with PET[18] and greater cortical atrophy[15] compared to males in clinical stages. In contrast, women in preclinical cohorts show a delayed and slower atrophy rate despite greater tau burden,[15,19] illustrating the complexity of this relationship. These findings highlight the need for more accurate investigations of sex and *APOE*-ε4 dependent effects to clarify the link between amyloid and atrophy rates in early disease stages.

The current study aims to determine the influence of global cortical amyloid burden on regional brain atrophy. To this end, we examined regional changes in brain volume and thickness in a non-demented population with predominantly cognitively normal subjects from the Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic Natural History Study (PNHS). We further investigated how the relationship between Aβ and atrophy is influenced by sex and *APOE*-ε4 carriership, and the additive predictive value of utilizing longitudinal amyloid-PET data. Finally, we estimated sample sizes needed to detect treatment effects on regional atrophy in clinical trials.

Materials and methods

Participants

Data for this study were drawn from the AMYPAD PNHS v202306 (*N*=1585).[20] The AMYPAD PNHS (EudraCT: 2018-002277-22) is a multi-center cohort of non-demented participants to determine the value of amyloid PET in clinical- and research settings; the study design has been described in detail previously.[21,22] Briefly, eligibility criteria for inclusion in the AMYPAD PNHS were no history of dementia (clinical dementia rating (CDR) < 1), age above 50 years, and being able to undergo an amyloid-PET and MRI scan. The studies were reviewed and approved by Medical Ethical Committee of the University Medical Center Amsterdam, location VUmc and all local sites. The studies were conducted according to the principles of the Helsinki Declaration of 1975, as revised in 2008, and all human participants gave written informed consent. Median time difference between the MRI and PET acquisition was 50 days (*IQR* 99 days). A subset of 684 participants underwent at least one follow-up PET and MRI, at a median follow-up of 3.4 years (± 1.4 years) after baseline. None of the study participants participated in clinical trials of anti-amyloid therapy throughout the duration of the study.

Aβ-PET Acquisition and Quantification

PET scans were acquired 90-110 minutes p.i. of 185 MBq (±10%) for [^{18}F]Flutemetamol and 350 MBq (±20%) for [^{18}F]Florbetaben, consisting of 4 frames of 5 minutes according to the standard protocol for each tracer.[23,24] Image analysis was performed centrally using IXICO's automated workflow. Briefly, PET frames were co-registered, averaged, and aligned to the corresponding MRI scan, which was parcellated using a subject-specific multi-atlas approach, i.e. the learning embeddings for atlas propagation (LEAP) parcellation procedure.[25] SUVr images were obtained using LEAP parcellation masks using the whole cerebellum as a

reference region in native space. In order to pool Aβ-PET data across sites, SUVr values were transformed to Centiloids (CL) using the standard Global Alzheimer's Association Interactive Network target region as a measure of global amyloid burden.[26]

Participants were grouped in low (CL≤20), intermediate (20<CL≤40), and elevated (CL>40) Aβ stages, corresponding to cut-points in current early secondary prevention trials[27] and based on derived cut-offs to define reliable worsening and detection of amyloid plaques on neuropathology.[28,29]

MRI Acquisition and Quantification

3D T1-weighted MR images were acquired on Philips (n=1340), Siemens (n=761) or GE HealthCare (n=24) scanners, all of which had a field strength of 3T. All longitudinal MRI were acquired on the same scanner model. Cortical segmentation was performed with FreeSurfer v7.1.1 (surfer.nmr.mgh.harvard.edu/), including motion correction, skull-stripping, brain parcellation and estimation of regional gray matter volume and thickness. The details of these procedures are described elsewhere.[30] The final IDPs included estimated total intracranial volume (eTIV), volumes of six sub- and allocortical regions of interest encompassing the lateral ventricles, thalamus, caudate, putamen, hippocampus and amygdala, as well as volume and thickness of 34 bilateral cortical regions of interest covering the whole cerebral cortex defined using the Desikan-Killiany atlas.[31] The parcellations were visually inspected, resulting in the exclusion of 36 subjects due to segmentation errors. IDPs were harmonized using neuroCombat v1.0.13 to remove batch effects, while preserving the biological effects of age, sex and global CDR scores (**Supplementary Fig. 1**).[32] Median follow-up time was 3.40 years (± 1.4 years) with a median of one follow-up visit.

Statistical analysis

All analyses were carried out in R v4.3.0 (www.r-project.org/). Differences in demographics between Aβ groups were assessed using ANOVA and Chi-Square tests for continuous- and categorical variables, respectively.

To assess the effect of baseline global cortical Aβ burden on subsequent regional neurodegeneration, linear mixed-effects models (LME) implemented via the R package "lme4" v1.1-35.3 with random slope and intercept were used. The main predictors included baseline amyloid burden (continuous CL), follow-up time, and their interaction while correcting for age and CDR at baseline, sex, eTIV, and their interaction; in R equation format: "GM Volume/Thickness ~ 1 + $\text{Centiloid}_{\text{Baseline}}$*Time + $\text{Age}_{\text{Baseline}}$ + Sex*eTIV + $\text{CDR}_{\text{Baseline}}$ + (1 + Time | Subject)".[33] Analyses were repeated in the subset of participants with longitudinal PET (*N*=684) to assess the added value of longitudinal Aβ-PET measurements, implemented through a time-varying rather than baseline Centiloid variable, by comparing the cross-sectional-only and longitudinal models using the Akaike Information Criterion derived from ANOVA. As a sensitivity analysis, these analyses were repeated in the CDR=0 subset (*N*=1099). The effect of *APOE*-e4 carriership and sex was assessed using two separate LME models with corresponding three-way interactions, i.e., amyloid*time**APOE* and amyloid*time*sex respectively. Finally, to assess sample sizes required to identify treatment effects (i.e., significant reductions in amyloid-related regional atrophy slopes) in prevention trials with 80% statistical power and a 5% significance threshold, the main models were repeated with CL groups to estimate absolute differences in rates of decline between normal and abnormal amyloid level groups, respectively representing a treatment and placebo group. Random coefficient regression model sample size calculations were performed according to the formula by Hu and colleagues,[34] implemented in the R package "longpower" v1.0.27. Treatment effects ranging from 20 to 30% were tested for two trial scenarios, namely

considering subjects showing intermediate or elevated Aβ accumulation for the treatment arm, respectively. Yearly measurements of regressor and outcome variables were assumed with a 1:1 placebo/treatment allocation ratio, equivalent population baseline values, total post-randomization dropout rate of 30% and a treatment range of four years, reflecting the intervention time of the AHEAD3-45 secondary prevention trials while also approximating the average follow-up time of our longitudinal data.[27]

All IDPs and CL values were z-scaled to obtain standardized regression coefficients. The significance level was set at $\alpha<0.05$ after applying the Benjamini-Hochberg procedure to correct for a false discovery rate.[35]

Results

Baseline demographics can be found in **Table 1**. The majority of individuals was cognitively unimpaired, reflected in the high frequency of CDR=0 scores (*N*=1070, 81%) and an average MMSE score of 28.82 (±1.54). Mean age was 68.18 (±8.78) years, 741 (56%) were female, and 117/260 (8.8%/19.6%) were considered to have intermediate and elevated Aβ, respectively. Follow-up time did not differ across amyloid groups with an overall median follow-up time of 3.4 (MD=1.40) years, although overall availability of follow-up data differed between amyloid groups with more longitudinal data available for subjects with low Aβ (**Supplementary Fig. 2**). Individuals with elevated Aβ more frequently had a CDR=0.5, lower MMSE scores, and a higher frequency of *APOE*-ε4 carriership compared to low Aβ individuals. Sex- and *APOE*-stratified demographic characterizations can be found in **Supplementary Table 1** and **Supplementary Table 2**, respectively.

Table 1. Demographics and Clinical Characteristics at Baseline

Variable	Overall (n = 1,329)[1]	Low Aβ (n = 952)[1]	Intermediate Aβ (n = 117)[1]	Elevated Aβ (n = 260)[1]	*p*

Age, years	68.18 (8.78)	66.47 (8.21)	70.64 (8.30)	73.33 (8.80)	<0.001[2]
Follow-Up, years	3.74 (1.87)	3.81 (1.88)	3.54 (1.91)	3.39 (1.75)	0.037[2]
(Missing)	585	355	58	172	
Sex, Female	741 (56%)	545 (57%)	63 (54%)	133 (51%)	0.2[3]
Education, years	14.56 (3.97)	14.71 (3.96)	14.47 (3.84)	14.05 (4.01)	0.075[2]
CDR					<0.001[3]
0 - Normal	1,070 (81%)	833 (88%)	90 (77%)	147 (57%)	
0.5 - Very mild	259 (19%)	119 (13%)	27 (23%)	113 (43%)	
CDR at Follow-Up					<0.001[4]
0 - Normal	572 (88%)	486 (92%)	40 (78%)	46 (68%)	
0.5 - Very mild	76 (12%)	45 (8%)	11 (22%)	20 (29%)	
1 - Mild	2 (0%)	0 (0%)	0 (0%)	2 (3%)	
(Missing)	679	421	66	192	
MMSE	28.82 (1.54)	29.06 (1.27)	28.68 (1.52)	27.91 (2.08)	<0.001[2]
(Missing)	108	61	8	39	
APOE-ε4 carriership (% carriers)	517 (40%)	300 (32%)	58 (51%)	159 (66%)	<0.001[3]
(Missing)	40	17	3	20	
Amyloid PET, centiloids	19.51 (32.33)	2.81 (8.37)	28.55 (6.05)	76.58 (27.48)	<0.001[2]
est. Total Intracranial Volume, cm³	1477.71 (178.43)	1476.68 (177.60)	1477.94 (196.79)	1481.38 (173.41)	0.7[2]

Abbreviations: Aβ, amyloid β; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination; PET, Positron Emission Tomography; Amyloid stages are defined based on a Centiloid value of under 20 for low, over 40 for elevated Aβ and a subsequent intermediate Aβ between 20 and 40 CL.
[1]Mean (SD); n / N (%)
[2]Kruskal-Wallis rank sum test
[3]Pearson's Chi-squared test
[4]Fisher's exact test

Effects of baseline Aβ burden on regional atrophy

LME results of the main models can be found in **Supplementary Table 3** and are visualized in **Figure 1**. Save one significant positive effect of time on temporal pole volume, there was a significant negative main effect of time on all investigated cortical and subcortical gray

matter volumes, suggesting widespread atrophy due to ageing-related neurodegeneration. This effect was most apparent in temporal and parietal regions as well as hippocampus and amygdala. Similar results were observed for cortical thickness, although posterior and anterior cingulate cortices showed thickening over time (**Figure 1A**). All main effects remained significant with comparable effect sizes in the CDR=0 subset (**Supplementary Fig. 3**).

Higher baseline cortical amyloid burden was associated to lower baseline volumes in widespread AD signature regions, comprising lateral-temporal lobes, precuneus, posterior cingulate, amygdala, and hippocampus. These main effects and patterns also emerged for cortical thickness but were more distributed and stronger compared to volumes (**Figure 1B**). This effect was largely absent in the CDR=0 subset (**Supplementary Fig. 3**).

Longitudinally (Centiloid*Time), higher baseline cortical amyloid burden was related to a widespread decrease of volume and thickness at follow-up across regions, with the strongest interaction effects observed in the posterior cingulate, fusiform and parahippocampal gyri. Subcortically, this effect was most pronounced in the hippocampus and amygdala, followed by the putamen. Lateral ventricles showed progressive widening in relation to cortical amyloid burden (**Figure 1C**). Except for hippocampal volume changes, most interaction effects were Aβ stage-dependent, shown by the significant slope difference between low and elevated, but not low and intermediate Aβ groups (**Supplementary Fig. 4**). In the CDR=0 subset, most effects remained significant with slightly lower effect sizes (**Supplementary Fig. 3**).

Stratification by sex & *APOE*-ε4 carriership

To investigate the effect of sex and *APOE*-ε4 carriership, the LME models were expanded with three-way interactions (i.e., amyloid*time*sex and amyloid*time**APOE)*. Effects of sex

on the relationship between amyloid and brain atrophy were limited, with female participants showing lower volume loss with increasing amyloid levels in the caudate nucleus compared to men (β=-0.007, SE=0.002; **Figure 2A**). For *APOE*-ε4-carriers, more severe cortical thinning as a result of amyloid increase was observed only in medial (β=-0.018, SE=0.005) and lateral (β=-0.014, SE=0.004) orbitofrontal cortices compared to non-carriers (**Figure 2B**).

Follow-Up Aβ-PET data does not improve brain atrophy predictions

LME results of the data subset (*N*=684) with available longitudinal Aβ-PET are shown in **Supplementary Fig. 5**. Including follow-up PET scans mostly did not improve predictions of volumetric or thickness measures, with significant improvements only in the prediction of volume of the posterior cingulate (ΔAIC = -9.55), caudal-anterior cingulate (ΔAIC = -4.97) and superior-frontal cortices (ΔAIC = -2.75; **Figure 2C**).

Power analyses

Sample sizes to detect treatment effects on regional atrophy in AD prevention trials were estimated with power analyses based on the difference in regional LME volume/thickness slopes between low and intermediate, or low and elevated Aβ participants (**Table 2**; **Figure 3**). Hippocampal volume was the best performing volumetric measure in both scenarios, requiring 778 or 432 subjects across the two scenarios per treatment arm to be powered to detect a 30% treatment efficacy and outperformed only be lateral ventricular volume in the elevated Aβ scenario, in which a 30% slowing of lateral ventricular growth could be detected with 130 patients per placebo/treatment arm.

Table 2. Sample size needed to detect treatment effects over 4 years

Phenotype/Region	20% Efficacy	25% Efficacy	30% Efficacy
1. Intermediate Aβ Scenario			
Thickness			
Superior temporal	2753	1762	1224
Bankssts	4335	2775	1927
Inferior parietal	5453	3490	2424
Supramarginal	6404	4099	2846
Volume			
Hippocampus	1751	1121	778
Lateral ventricle	2103	1346	935
Supramarginal	3924	2512	1744
Inferior parietal	4043	2588	1797
2. Elevated Aβ Scenario			
Thickness			
Fusiform	1622	1038	721
Precuneus	1972	1262	877
Superior parietal	2489	1593	1106
Cuneus	2618	1675	1164
Volume			
Lateral ventricle	292	187	130
Hippocampus	971	622	432
Fusiform	1136	727	505
Posterior cingulate	1630	1044	725

Discussion

In this longitudinal prospective pan-European cohort study, we investigated the effect of baseline cortical amyloid burden on subsequent cortical and subcortical brain atrophy in a large non-demented and predominantly clinically normal population. We showed that baseline amyloid was predictive of widespread atrophy in several regions, most notably the medial-temporal lobes, fusiform, cingulate, and precuneus cortices, with thickness being a

more sensitive or affected measure than volume. Further, we demonstrated that this relationship is mostly independent of sex and *APOE* genotype. Finally, we showed that in order to find realistic treatment effects in early prevention trials, hippocampal and lateral ventricular volume are the most sensitive phenotypes followed by cortical thickness of the medial-temporal or fusiform gyri.

The observed widespread atrophy suggests an early detrimental effect of amyloid on brain volume and thickness, and corroborates the importance of early intervention to prevent subsequent atrophy [36]. Amyloid-related longitudinal changes were more strongly observed on measures of cortical thickness, and most prominently in the fusiform, precuneus, and superior temporal cortices, matching those ROI's previously selected in a cortical thickness meta-ROI to distinguish MCI/AD from healthy controls [11]. In contrast, previous whole-brain investigations of the relationship between amyloid and atrophy in preclinical or prodromal AD cohorts have largely focused on volume [3,4]. These studies revealed similar affected regions, such as the precuneus, medial and lateral-temporal cortices, and posterior and middle cingulate. Clinical anti-amyloid trials mostly use global, lateral ventricle or hippocampal volumes as secondary outcomes [27], and our results also confirm lateral ventricular and hippocampal volume to be potential surrogate outcomes in secondary prevention trials for subjects with elevated, but not intermediate levels of Aβ burden.

In addition to these regions, we found an effect of amyloid on subsequent volume loss or thinning of the inferior and superior-parietal lobules and medial-orbitofrontal cortex, previously identified as seeding regions in parietal and frontal subtypes of amyloid propagation [37]. Beyond the more evident effect of pathology on AD signature regions, these findings suggest a local effect of amyloid deposition on cortical atrophy.

When looking at the interacting effect of common candidate stratification factors in clinical trials, we found sex-dependent effects only in volume of the caudate nucleus. Sex-specific alterations in caudate nucleus functional connectivity have been previously observed, with women exhibiting stronger caudate-frontal functional coupling in MCI [38], suggesting early sex-specific subcortical changes which possibly result in impairment of executive functions [39]. Predominantly, however, the lack of sex-dependent associations in other regions suggests that amyloid-associated atrophy may represent a sex-independent measure of disease progression, while other markers such as tau PET exhibit differential spatial extent [40]. We further observed that amyloid-related orbitofrontal atrophy is accelerated in *APOE*-ε4 carriers, in line with previous reports of ε4 predominance in an AD frontal subtype of amyloid accumulation [37], suggesting a spatial association between amyloid deposition and atrophy.

To frame our observations in the context of clinical trials, we showed that the most likely detectable treatment effects would be a reduction of hippocampal and lateral ventricular volume loss and fusiform thickness in patients with elevated amyloid levels over 40 CL at baseline, or a reduction of hippocampal volume loss and superior temporal thinning for the intermediate Aβ scenario. Our sample size calculations estimate that with a 4-year anti-amyloid treatment, one could demonstrate a 30% slowing of hippocampal atrophy with 432 participants per treatment and control arm. In context, current prevention trials randomize around 1000 participants to treatment and control arms, making detections of up to 30% hippocampal atrophy slowing feasible [27,41]. Based on our results, however, a lower efficacy than 30% or treatment effects in other brain regions or in whole brain volume would realistically not be accurately detectable in either intermediate or elevated amyloid preclinical populations. A second caveat for the inclusion of atrophy as an immediate outcome measure in such trials is that paradoxically, structural MRI results from anti-amyloid targeting trials in

clinical populations have so far reported either insignificant or accelerated volume decreases [6], despite other fluid markers of neurodegeneration and cognitive markers indicating beneficial changes. These unexpected findings might be caused by off-target reduction of inflammatory responses, resulting in “pseudo-atrophy” [42], with later discussions observing that such findings majorly occur in otherwise successful trials, designating it more specifically as “amyloid-removal related pseudo-atrophy” [43]. While treatment with donanemab in the TRAILBLAZER-ALZ 2 trial in early symptomatic AD patients showed a negative effect on whole brain volume, it did result in mild temporary slowing of hippocampal volume loss compared to the placebo group [44]. It is not known, however, whether such pseudo-atrophic effects could also occur in secondary prevention trials in which pathophysiological and inflammatory processes are likely not as severe. In the case that the hypothesis of “amyloid-removal related pseudo-atrophy” is empirically substantiated, there would be a need for follow-up MRI assessments after the treatment period to accurately assess whether treatment-related atrophy reductions occurred. Together with our results, this evidence suggests that region-specific atrophy, rather than whole brain changes, could serve as a better marker for treatment response.

Our findings represent the largest population to date to address the relationship between amyloid and atrophy in preclinical AD, enabling the inclusion of relevant covariates and stratification analyses such as the concurrent investigation of regional cortical volume and thickness. However, several methodological limitations need to be considered. First, the lack of a marker for neurofibrillary tangles, more closely related to patterns of atrophy in clinical AD than cortical Aβ [45], did not allow us to disentangle the individual contributions of these pathological factors to brain atrophy. However, the observed associations in the CDR=0 subset with a presumably relatively lower tau burden advocate for a partially independent effect of amyloid on neurodegeneration and qualify atrophy measures as a relevant marker

for anti-amyloid treatment efficacy. The previously observed additive effect of vascular risk to the association between Aβ and atrophy was also not taken into account in this work and warrants future research [46]. Finally, the availability of follow-up data was skewed towards low Aβ burden participants, with over 80% of follow-up data coming from the low Aβ group at baseline (**Supplementary Fig. 2**). This bias may explain the overall lack of model improvement when including longitudinal PET data, as previous studies have highlighted the benefits of using follow-up PET data [47]. While the acquired data originated from 17 European sites and was acquired with different MRI scanners and Aβ-PET radiotracers, possible batch effects were minimized by utilizing state-of-the-art harmonization techniques [26,32].

In the present study, we investigated regional differences through the gyral based Desikan-Killiany atlas; future research could focus on more fine-grained parcellations such as hippocampal subfields, with more focal CA1 and subiculum atrophy having been shown to occur before other subfields in the amyloid cascade [48]. Additionally, as the global Centiloid metric is a robust measure [49] and commonly used in previous and ongoing trials, we did not investigate regional measures of amyloid burden. However, evidence exists regarding the presence of different amyloid-PET spatial-temporal subtypes [37]. It would be of interest to investigate whether regional amyloid-PET quantifications further improve atrophy prediction models. Beyond these aspects, rather than assuming a single pattern of atrophy due to amyloid, subtypes of atrophy [50] in relation to amyloid accumulation could be investigated.

Conclusions

We demonstrated the influence of cortical amyloid on brain atrophy in several regions in a non-demented population. Importantly, these associations appeared to be mostly independent of sex and *APOE* ε4-genotype. Our results highlight cortical thickness as a more affected biomarker compared to volume, while secondary prevention trials are most powered to find

hippocampal and lateral ventricle volume sparing. Overall, our findings emphasize the importance of early intervention strategies to mitigate amyloid-related neurodegeneration, with implications for the design and interpretation of clinical trials aimed at preventing AD.

Data availability

Data for this study were drawn from the AMYPAD PNHS v202306, available on the AD Workbench and can be requested via the AD Workbench FAIR portal under https://fair.addi.addatainitiative.org/#/data/datasets/amypad_pnhs__harmonised_and_derived__v202306. The data access request procedure is described under https://doi.org/10.5281/zenodo.7962924.

Funding

The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

This study was supported by the Alzheimer's Disease Data Initiative (ADDI).

Competing interests

Robin Wolz reports a relationship with IXICO plc that includes: employment. Sylke Grootoonk reports a relationship with IXICO plc that includes: employment. Craig Ritchie reports a relationship with Scottish Brain Sciences that includes: board membership and equity or stocks. Craig Ritchie reports a relationship with Biogen Inc that includes: consulting or advisory fees. Craig Ritchie reports a relationship with Eisai Inc that includes: consulting or advisory fees. Craig Ritchie reports a relationship with MSD that includes: consulting or advisory fees. Craig Ritchie reports a relationship with Actinogen that includes: consulting or advisory fees. Craig Ritchie reports a relationship with Roche that includes: consulting or advisory fees. Craig Ritchie reports a relationship with Eli Lilly and Company that includes: consulting or advisory fees. Mercè Boada reports a relationship with Grifols that includes:

consulting or advisory fees, board membership, and speaking and lecture fees. Mercè Boada reports a relationship with Araclon Biotech that includes: consulting or advisory fees, board membership, and speaking and lecture fees. Mercè Boada reports a relationship with Roche that includes: consulting or advisory fees, board membership, and speaking and lecture fees Mercè Boada reports a relationship with Biogen that includes: consulting or advisory fees and board membership. Mercè Boada reports a relationship with Eli Lilly that includes: consulting or advisory fees and board membership. Mercè Boada reports a relationship with Merck that includes: consulting or advisory fees and board membership. Mercè Boada reports a relationship with Zambon that includes: consulting or advisory fees and board membership. Mercè Boada reports a relationship with Novo Nordisk that includes: consulting or advisory fees, board membership, and speaking and lecture fees. Mercè Boada reports a relationship with Bioiberica that includes: board membership. Mercè Boada reports a relationship with Eisai that includes: board membership. Mercè Boada reports a relationship with Servier that includes: board membership and speaking and lecture fees. Mercè Boada reports a relationship with Schwabe Pharma that includes: board membership. Mercè Boada reports a relationship with Nutricia that includes: speaking and lecture fees. Marta Marquié reports a relationship with Instituto de Salud Carlos III (ISCIII): funding or grants. Marta Marquié reports a relationship with F. Hoffmann-La Roche Ltd.: travel reimbursement. Marta Marquié reports a relationship with Araclon Biotech-Grifols that includes: board membership. Wiesje van der Flier reports a relationship with Oxford Health Policy Forum CIC: consulting or advisory fees. Wiesje van der Flier reports a relationship with Roche: consulting or advisory fees. Wiesje van der Flier reports a relationship with Biogen MA Inc: consulting or advisory fees. Wiesje van der Flier reports a relationship with Eisai: consulting or advisory fees. Wiesje van der Flier reports a relationship with Biogen MA Inc, Danone, Eisai, WebMD Neurology, Novo Nordisk, and Springer Healthcare that includes: speaking and lecture fees. Wiesje van der Flier reports a relationship with Roche and Eli Lilly that includes: board membership. Wiesje van der Flier reports a relationship with Novo Nordisk that includes: board membership. Wiesje van der Flier reports a relationship with PAVE and Think Brain Health that includes: board membership. Bernard J Hanseeuw reports a relationship with Biogen that includes: consulting or advisory fees. Bernard J Hanseeuw reports a relationship with Eisai that includes: consulting or advisory fees. Bernard J Hanseeuw reports a relationship with Roche that includes: consulting or advisory fees. Pablo Martinez-Lage reports a relationship with Eli Lilly that includes: board membership, speaking and lecture fees, and travel reimbursement. Pablo Martinez-Lage reports a relationship with Nutricia that

includes: board membership, speaking and lecture fees, and travel reimbursement. Pablo Martinez-Lage reports a relationship with Roche that includes: board membership, speaking and lecture fees, and travel reimbursement. Pablo Martinez-Lage reports a relationship with Eisai that includes: board membership, speaking and lecture fees, and travel reimbursement. Pablo Martinez-Lage reports a relationship with Grifols that includes: board membership, speaking and lecture fees, and travel reimbursement. Pablo Martinez-Lage reports a relationship with Esteve that includes: board membership, speaking and lecture fees, and travel reimbursement. Pierre Payoux reports a relationship with GE Healthcare that includes: consulting or advisory fees and research support. Pieter Jelle Visser reports a relationship with Eli Lilly that includes: board membership. Pieter Jelle Visser reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory fees. Pieter Jelle Visser reports a relationship with Bristol-Myers Squibb that includes: Funding or grants. Pieter Jelle Visser reports a relationship with GE Healthcare that includes: Funding or grants. Pieter Jelle Visser reports a relationship with the European Commission that includes: Funding or grants. Pieter Jelle Visser reports a relationship with other European funding programs that includes: Funding or grants. Michael Schöll reports a relationship with Knut and Alice Wallenberg Foundation,the Swedish Research Council, European Union programs that includes: Funding or grants. Michael Schöll reports a relationship with the Swedish Research Council that includes: Funding or grants. Michael Schöll reports a relationship with European Union programs that includes: Funding or grants. Michael Schöll reports a relationship with Roche that includes: board membership. Michael Schöll reports a relationship with Novo Nordisk that includes: board membership. Michael Schöll reports a relationship with Bioarctic that includes: speaking and lecture fees. Michael Schöll reports a relationship with Eisai that includes: speaking and lecture fees. Michael Schöll reports a relationship with Genentech that includes: speaking and lecture fees. Michael Schöll reports a relationship with Novo Nordisk that includes: speaking and lecture fees. Michael Schöll reports a relationship with Roche that includes: speaking and lecture fees. Andrew W. Stephens Collij reports a relationship with Life Molecular Imaging that includes: employment. Christopher Buckley reports a relationship with GE Healthcare that includes: employment. Gill Farrar reports a relationship with GE Healthcare that includes: employment. Lyduine E. Collij reports a relationship with GE Healthcare and Springer Healthcare that includes: research support. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Schwarz AJ, Sundell KL, Charil A, et al. Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. *Alzheimers Dement*. 2019;5:328-337. doi:10.1016/j.trci.2019.05.007

2. Bejanin A, Schonhaut DR, La Joie R, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. *Brain*. 2017;140(12):3286-3300. doi:10.1093/brain/awx243

3. Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW, Alzheimer's Disease NeuroImaging Initiative. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. *Brain*. 2011;134(Pt 4):1077-1088. doi:10.1093/brain/awr044

4. Chételat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. *Neurology*. 2012;78(7):477-484. doi:10.1212/WNL.0b013e318246d67a

5. La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. *Sci Transl Med*. 2020;12(524). doi:10.1126/scitranslmed.aau5732

6. Alves F, Kalinowski P, Ayton S. Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs: A Systematic Review and Meta-analysis. *Neurology*. 2023;100(20):e2114-e2124. doi:10.1212/WNL.0000000000207156

7. Fletcher E, Villeneuve S, Maillard P, et al. β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. *Neurobiol Aging*. 2016;40:173-180. doi:10.1016/j.neurobiolaging.2016.01.133

8. Bachmann D, Buchmann A, Studer S, et al. Age-, sex-, and pathology-related variability in brain structure and cognition. *Transl Psychiatry*. 2023;13(1):278. doi:10.1038/s41398-023-02572-6

9. Mattsson N, Insel PS, Nosheny R, et al. Emerging β-amyloid pathology and accelerated cortical atrophy. *JAMA Neurol*. 2014;71(6):725-734. doi:10.1001/jamaneurol.2014.446

10. Martikainen IK, Kemppainen N, Johansson J, et al. Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. *AJNR Am J Neuroradiol*. 2019;40(1):80-85. doi:10.3174/ajnr.A5891

11. Schwarz CG, Gunter JL, Wiste HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. *NeuroImage Clin*. 2016;11:802-812. doi:10.1016/j.nicl.2016.05.017

12. Xie L, Wisse LEM, Das SR, et al. Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease. *Hum Brain Mapp*. 2020;41(16):4704-4717. doi:10.1002/hbm.25151

13. Kepp KP, Sensi SL, Johnsen KB, et al. The Anti-Amyloid Monoclonal Antibody

Lecanemab: 16 Cautionary Notes. *J Alzheimers Dis*. 2023;94(2):497-507. doi:10.3233/JAD-230099

14. Yadollahikhales G, Rojas JC. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update. *Neurotherapeutics*. 2023;20(4):914-931. doi:10.1007/s13311-023-01405-0

15. Sauty B, Durrleman S. Impact of sex and APOE-ε4 genotype on patterns of regional brain atrophy in Alzheimer's disease and healthy aging. *Front Neurol*. 2023;14:1161527. doi:10.3389/fneur.2023.1161527

16. Mattsson N, Eriksson O, Lindberg O, et al. Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. *Neurobiol Aging*. 2018;71:81-90. doi:10.1016/j.neurobiolaging.2018.07.003

17. Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimers Dement*. 2023;19(2):658-670. doi:10.1002/alz.12694

18. Wisch JK, Meeker KL, Gordon BA, et al. Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). *Alzheimer Dis Assoc Disord*. 2021;35(2):164-168. doi:10.1097/WAD.0000000000000393

19. Buckley RF, Mormino EC, Rabin JS, et al. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. *JAMA Neurol*. 2019;76(5):542-551. doi:10.1001/jamaneurol.2018.4693

20. García DV. AMYPAD PNHS - Integrated dataset (Raw) v202306. Published online 2023. doi:10.5281/ZENODO.8017084

21. Lopes Alves I, Collij LE, Altomare D, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. *Alzheimers Dement*. 2020;16(5):750-758. doi:10.1002/alz.12069

22. Collij LE, Farrar G, Valléz García D, et al. The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact. *Front Neurol*. 2022;13:1063598. doi:10.3389/fneur.2022.1063598

23. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. *Lancet Neurol*. 2011;10(5):424-435. doi:10.1016/S1474-4422(11)70077-1

24. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. *JAMA Neurol*. 2015;72(3):287-294. doi:10.1001/jamaneurol.2014.4144

25. Wolz R, Aljabar P, Hajnal JV, Hammers A, Rueckert D, Alzheimer's Disease Neuroimaging Initiative. LEAP: learning embeddings for atlas propagation. *Neuroimage*. 2010;49(2):1316-1325. doi:10.1016/j.neuroimage.2009.09.069

26. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative

amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1-15.e1-4. doi:10.1016/j.jalz.2014.07.003

27. Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. *Alzheimers Dement*. 2023;19(4):1227-1233. doi:10.1002/alz.12748

28. Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimers Dement*. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005

29. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. *Brain*. 2015;138(Pt 7):2020-2033. doi:10.1093/brain/awv112

30. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage*. 2012;61(4):1402-1418. doi:10.1016/j.neuroimage.2012.02.084

31. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*. 2006;31(3):968-980. doi:10.1016/j.neuroimage.2006.01.021

32. Fortin JP, Cullen N, Sheline YI, et al. Harmonization of cortical thickness measurements across scanners and sites. *Neuroimage*. 2018;167:104-120. doi:10.1016/j.neuroimage.2017.11.024

33. Dhamala E, Ooi LQR, Chen J, et al. Proportional intracranial volume correction differentially biases behavioral predictions across neuroanatomical features, sexes, and development. *Neuroimage*. 2022;260:119485. doi:10.1016/j.neuroimage.2022.119485

34. Hu N, Mackey H, Thomas R. Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. *Biom J*. 2021;63(4):806-824. doi:10.1002/bimj.202000184

35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc*. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x

36. Aisen PS, Cummings J, Doody R, et al. The Future of Anti-Amyloid Trials. *J Prev Alzheimers Dis*. 2020;7(3):146-151. doi:10.14283/jpad.2020.24

37. Collij LE, Salvadó G, Wottschel V, et al. Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis. *Neurology*. 2022;98(17). doi:https://www.neurology.org/doi/10.1212/WNL.0000000000200148

38. Yang Z, Caldwell JZK, Cummings JL, et al. Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment. *Front Psychiatry*. 2022;13:804168. doi:10.3389/fpsyt.2022.804168

39. Macfarlane MD, Looi JCL, Walterfang M, et al. Executive dysfunction correlates with caudate nucleus atrophy in patients with white matter changes on MRI: a subset of

LADIS. *Psychiatry Res*. 2013;214(1):16-23. doi:10.1016/j.pscychresns.2013.05.010

40. Pereira JB, Harrison TM, La Joie R, Baker SL, Jagust WJ. Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. *Eur J Nucl Med Mol Imaging*. 2020;47(9):2155-2164. doi:10.1007/s00259-019-04669-x

41. Sperling RA, Donohue MC, Raman R, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. *N Engl J Med*. 2023;389(12):1096-1107. doi:10.1056/NEJMoa2305032

42. Barkhof F, Knopman DS. Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?: Neurology: Vol 100, No 20. *Neurology*. 2023;100(20):941-942. doi:10.1212/WNL.0000000000207268

43. Belder CRS, Boche D, Nicoll JAR, et al. Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy. *Lancet Neurol*. 2024;23(10):1025-1034. doi:10.1016/S1474-4422(24)00335-1

44. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023;330(6):512-527. doi:10.1001/jama.2023.13239

45. Gordon BA, McCullough A, Mishra S, et al. Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. *Alzheimers Dement*. 2018;10:245-252. doi:10.1016/j.dadm.2018.02.003

46. Rabin JS, Pruzin J, Scott M, et al. Association of β-amyloid and vascular risk on longitudinal patterns of brain atrophy. *Neurology*. 2022;99(3):e270-e280. doi:10.1212/WNL.0000000000200551

47. Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging Initiative. Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease. *Neurology*. 2021;96(9):e1347-e1357. doi:10.1212/WNL.0000000000011524

48. Zhang L, Mak E, Reilhac A, et al. Longitudinal trajectory of Amyloid-related hippocampal subfield atrophy in nondemented elderly. *Hum Brain Mapp*. 2020;41(8):2037-2047. doi:10.1002/hbm.24928

49. Shekari M, Vállez García D, Collij LE, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. *Alzheimers Dement*. Published online July 4, 2024. doi:10.1002/alz.13883

50. Risacher SL, Anderson WH, Charil A, et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. *Neurology*. 2017;89(21):2176-2186. doi:10.1212/WNL.0000000000004670

Figure legends

Figure 1 Main & interaction effects of time & amyloid at baseline on regional volumes & thicknesses. FDR-thresholded LME **(A)** main effect of time, **(B)** main effect of baseline cortical Aβ and **(C)** interaction effect of time and Aβ on cortical thickness, cortical volume and subcortical volume. Surface projections show the left lateral and left medial cortex respectively, representative of averaged bilateral effects.

Figure 2 Modulating effects of APOE ε4, sex & benefits of longitudinal PET scans. FDR-thresholded regression coefficients of the interaction effects of **(A)** Time × Aβ × APOE ε4 (Carrier > Non-Carrier), **(B)** Time × Aβ × Sex (Male > Female). **(C)** Difference in AIC between the default baseline PET model and longitudinal PET model.

Figure 3 Required sample sizes to detect regional treatment effects. Sample size requirements to find effect sizes ranging from 10% to 30% with 80% statistical power are plotted for two 48 month secondary prevention anti-amyloid trials. For both scenari os, the most powered region for each phenotype (GM volume and thickness) are plotted with whole GM volume as a reference metric.

Figure 1. Main & interaction effects of time & amyloid at baseline on regional volumes & thicknesses.



FDR-thresholded LME **A.** main effect of time, **B.** main effect of baseline cortical Aβ and **C.** interaction effect of time and Aβ on cortical thickness, cortical volume and subcortical volume. Surface projections show the left lateral and left medial cortex respectively, representative of averaged bilateral effects.

Figure 2. Modulating effects of *APOE* ε4, sex & benefits of longitudinal PET scans.



FDR-thresholded regression coefficients of the interaction effects of A. Time × Aβ × APOE ε4 (Carrier > Non-Carrier), B. Time × Aβ × Sex (Male > Female). C. Difference in AIC between the default baseline PET model and longitudinal PET model.

Figure 3. Required sample sizes to detect regional treatment effects.





Sample size requirements to find effect sizes ranging from 10% to 30% with 80% statistical power are plotted for two 48 month secondary prevention anti-amyloid trials. For both scenarios, the most powered region for each phenotype (GM volume and thickness) are plotted with whole GM volume as a reference metric.